A new study published in PLoS ONE showed that one in four patients with hepatitis C virus infection who apply for treatment of the infection is initially denied.
“Delay in access may further challenge our ability to cure hepatitis C in this country,” Joseph K. Lim, MD, associate professor of medicine and director of the Yale Viral Hepatitis Program at Yale University, said in a press release. “Some patients are told they must wait until they have advanced liver disease before they can undergo potentially curative treatment. We hope these data may help inform national policy discussions on promoting more rational, patient-centered approaches to HCV treatment access.”
“This is the first study to our knowledge assessing real-world access to interferon-free [direct-acting antiviral] regimens in established cohorts of patients with chronic HCV seeking antiviral therapy,” the researchers wrote. “These results contribute to the limited data available addressing proportion of patients successfully obtaining drug authorization through public and private insurance carriers, time to approval, and predictors for approval. … Further studies are warranted to investigate the impact of evolving drug authorization policies by Medicare/Medicaid and private payers on access to curative HCV therapies such as [sofosbuvir and ledipasvir].” – by Melinda Stevens.
Do A, et al. PLoS One. 2015;doi:10.1371/journal.pone.0135645.
Read more....
Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.
For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials click here
Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.
Alan Franciscus
Editor-in-Chief
HCV Advocate
Showing posts with label denied treatment. Show all posts
Showing posts with label denied treatment. Show all posts
Saturday, August 29, 2015
Monday, January 19, 2015
Canada: Vancouver man denied access to lifesaving new Hepatitis C drugs
A resident of Vancouver’s Downtown Eastside is speaking out about the cost of treatments for Hepatitis C. Brody Williams says the only effective options left cost close to $100,000.
Brody Williams has battled the disease for years, undergoing numerous treatments. He’s one of 200,000 Canadians struggling with the virus.
But Williams isn’t getting the drugs. They come with a price tag of $75,000 – $100,000 for a course, and neither the federal Ministry of Indian Affairs, nor B.C.’s medical system will pay because he’s had four different drug treatment protocols already.
Read more...
Brody Williams has battled the disease for years, undergoing numerous treatments. He’s one of 200,000 Canadians struggling with the virus.
But Williams isn’t getting the drugs. They come with a price tag of $75,000 – $100,000 for a course, and neither the federal Ministry of Indian Affairs, nor B.C.’s medical system will pay because he’s had four different drug treatment protocols already.
Read more...
Subscribe to:
Posts (Atom)